Financial Performance and Corporate Developments – Q3 2026
Company Overview NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical‑stage pharmaceutical company headquartered in Wilmington, United States. The company focuses on the research, development, and commercialization of investigational medicines and vaccines for COVID‑19, respiratory conditions, suicidal depression, and PTSD. NRX’s market capitalization was approximately $91 million as of the close on 15 November 2026, with a share price of $2.15. The firm’s price‑to‑earnings ratio was negative at –2.81, reflecting its ongoing loss‑making operations.
Third‑Quarter 2026 Financial Highlights
| Metric | 2025 (Year‑to‑Date) | 2026 (Year‑to‑Date) |
|---|---|---|
| Net patient‑service revenue | $0.2 million | $1.2 million |
| Net loss | $5.9 million (–$0.27 EPS) | $2.2 million (–$0.05 EPS) |
| Operating loss | $4.0 million | $8.1 million |
| Cash, cash equivalents, and marketable securities | $7.8 million | $19.8 million |
- Revenue Growth – Net patient‑service revenue increased sixfold in the first nine months of 2026, driven by the commencement of commercial sales of a preservative‑free ketamine product following its FDA approval in October 2026.
- Profitability Metrics – Gross‑profitability improved as the company reported a GAAP earnings‑per‑share of –$0.05, which exceeded analyst expectations by $0.16. However, revenue of $1.16 million fell short of forecasts by $0.13 million.
- Loss Reduction – The net loss narrowed from $5.9 million in 2025 to $2.2 million in 2026, reflecting both improved revenue performance and cost‑management measures.
Operational Milestones
- FDA Approval of Preservative‑Free Ketamine – The United States Food and Drug Administration granted approval in October 2026, ahead of the company’s targeted November 10 goal date. Commercial sales began the week of November 9, with the first order received and shipments scheduled for January 2027.
- DARPA Contract for NRx Defense Systems – The company secured an $11.25 million contract from the Defense Advanced Research Projects Agency (DARPA) for a Phase 3 trial of the SPARC‑TMS technology. This contract is expected to support the development of a novel treatment platform for neurological conditions.
- Strategic Collaborations – NRX plans to submit a rolling application for its NRX‑100 drug candidate by the end of 2026, backed by a partnership with Yale University. The company also introduced a subcutaneous ketamine candidate, NRX‑200, with initial human testing slated for September 2027.
Cash Position and Capital Structure
- Cash Reserves – As of September 30 2026, the company held $19.8 million in cash, cash equivalents, and market‑able securities, up from $7.8 million at the end of 2025. This liquidity position provides a buffer for ongoing R&D activities and commercial launch costs.
- Debt and Equity – The balance sheet reported no convertible debt. The company’s common‑stock offering in June 2026 raised approximately $22.3 million in gross proceeds, representing about 24 % of the company’s market capitalization at the time of issuance.
Forward‑Looking Statements
NRX’s management indicated that the company aims to achieve profitability in 2027. Funding for future innovation will be pursued through non‑dilutive sources wherever possible. The rollout of the ketamine product line is expected to continue through early 2027, with additional formulations (e.g., NRX‑200) planned for later in the year.
Summary NRX Pharmaceuticals demonstrated a marked improvement in revenue and a reduction in net loss during the third quarter of 2026. The FDA approval of a preservative‑free ketamine formulation, combined with the commencement of commercial sales, underpins the company’s revenue growth. While the firm remains loss‑making, its cash reserves have expanded significantly, and strategic partnerships and contracts are expected to support future development and commercialization efforts.




